Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Pharmacokinetically-Guided, Dose Escalation Study to Assess the Safety and Tolerability of Dexanabinol in Patients With Advanced Solid Tumours

NCT01489826 is registered in ClinicalTrials.gov with e-Therapeutics PLC as lead sponsor.

NCT NCT01489826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01489826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Pharmacokinetically-Guided, Dose Escalation Study to Assess the Safety and Tolerability of Dexanabinol in Patients With Advanced Solid Tumours
Lead sponsor
e-Therapeutics PLC
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2012
Completion date
July 31, 2015
Enrollment
40 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumour